These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30131975)

  • 1. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC; Alvarado MD; Lancaster RB; Fraser Symmans W; Mukhtar R; Wong JM; Ewing CA; Potter DA; Tuttle TM; Hieken TJ; Carter JM; Jakub JW; Kaplan HG; Buchanan CL; Jaskowiak NT; Sattar HA; Mueller J; Nanda R; Isaacs CJ; Pohlmann PR; Lynce F; Tousimis EA; Zeck JC; Lee MC; Lang JE; Mhawech-Fauceglia P; Rao R; Taback B; Chen M; Kalinsky KM; Hibshoosh H; Killelea B; Sanft T; Hirst GL; Asare S; Matthews JB; Perlmutter J; Esserman LJ;
    NPJ Breast Cancer; 2018; 4():26. PubMed ID: 30131975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: Results of a survey amongst breast cancer specialists.
    Simons JM; Maaskant-Braat AJG; Luiten EJT; Leidenius MHK; van Nijnatten TJA; Boelens PG; Koppert LB; van der Pol CC; van de Velde CJH; Audisio RA; Smidt ML
    Eur J Surg Oncol; 2020 Jan; 46(1):53-58. PubMed ID: 31434617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
    Le-Petross HT; McCall LM; Hunt KK; Mittendorf EA; Ahrendt GM; Wilke LG; Ballman KV; Boughey JC
    AJR Am J Roentgenol; 2018 Mar; 210(3):669-676. PubMed ID: 29381381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
    Kuerer HM; Newman LA; Fornage BD; Dhingra K; Hunt KK; Buzdar AU; Ames FC; Ross MI; Feig BW; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 1998 Dec; 5(8):673-80. PubMed ID: 9869512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
    Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
    Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
    Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
    Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy.
    Tinterri C; Canavese G; Bruzzi P; Dozin B
    Contemp Clin Trials Commun; 2020 Mar; 17():100496. PubMed ID: 31872159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary staging prior to neoadjuvant chemotherapy: the roles of sentinel lymph node biopsy and axillary ultrasonography.
    Lee MC; Joh JE; Chau A
    Cancer Control; 2012 Oct; 19(4):277-85. PubMed ID: 23037495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary management of the axilla in breast cancer.
    Nurudeen S; Hunt KK
    Clin Adv Hematol Oncol; 2018 Dec; 16(12):823-831. PubMed ID: 30843891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center.
    Garcia-Etienne CA; Ferrari A; Della Valle A; Lucioni M; Ferraris E; Di Giulio G; Squillace L; Bonzano E; Lasagna A; Rizzo G; Tancredi R; Scotti Foglieni A; Dionigi F; Grasso M; Arbustini E; Cavenaghi G; Pedrazzoli P; Filippi AR; Dionigi P; Sgarella A
    Eur J Surg Oncol; 2020 Jan; 46(1):15-23. PubMed ID: 31445768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.